



Proteomics International
LABORATORIES LTD

ASX Release
14 September 2026

ASX code: PIQ

Promarker®D and Promarker®Eso Commercial Rollout Update

Highlights

- Proteomics International is pleased to announce the controlled market release of Promarker®D and Promarker®Eso in WA and NT, under Proteomics International's exclusive pathology distribution agreement with Healius Limited (ASX: HLS) for all Promarker® tests.
- Operational and systems readiness with Healius progressing to support national rollout.
- Broader commercial sales expected to follow in Q2 FY27, subject to successful completion of implementation activities.
- Australian patient pricing has been initially set at \$495 for Promarker®D and \$997 for Promarker®Eso. The tests will initially be available on a private-pay basis.
- Promarker®Endo assay refinement activities are progressing, with achievement of the next clinical milestone subject to successful completion of the validation program.

Proteomics International Laboratories Ltd (ASX: PIQ) ("Proteomics International" or "the Company") provides an update on the implementation of its national distribution agreement with Healius Limited ("Healius") (ASX: HLS) for commercial rollout of the Promarker product portfolio.

This update follows the Company's announcement on 22 July 2026 that Healius had been appointed exclusive Australian pathology distribution partner for the Promarker portfolio of tests.

The agreement provides Proteomics with access to Healius' nationwide network of approximately 1900 collection centres and established partner relationships. The agreement represents the first national commercial distribution partnership secured for the Promarker® portfolio and establishes a national distribution pathway for commercial implementation across Australia. It is intended to support national access to the Promarker® portfolio through existing pathology collection and distribution infrastructure without requiring Proteomics International to establish its own national specimen collection network.

As the Promarker® portfolio is at an early stage of commercialisation, the revenue that may be generated under the distribution agreement cannot be reliably estimated at this time. The Company will update the market on material developments in accordance with its continuous disclosure obligations.

Controlled market release in WA and NT to commence

Controlled market release of Proteomics' Promarker®D and Promarker®Eso in WA and NT commences today, Monday 14 September 2026, under Proteomics International's exclusive pathology distribution agreement with Healius.

The controlled release in WA and NT will support operational and systems readiness ahead of national rollout.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Subject to completion of implementation activities, broader commercial sales are expected to follow in Q2 FY27.

The Promarker® tests will be offered to patients on a private-pay basis with the Australian patient pricing initially set at \$495 for Promarker®D and \$997 for Promarker®Eso.

Blood Test	Use
Promarker®D	Risk assessment for diabetic kidney disease up to four years before clinical symptoms appear.
Promarker®Eso	Assists in ruling out oesophageal cancer in patients with chronic reflux.
Promarker®Endo	Assists in the diagnosis of endometriosis.

The operating model remains consistent with the distribution agreement, with Proteomics International responsible for laboratory testing, clinical reporting, scientific support and quality and regulatory compliance. Through its market-leading footprint of collection centres nationally, Healius will provide specimen collection, pathology distribution and commercial delivery to primary care and specialist referrers.

Commentary

Proteomics International CEO and Managing Director, David Morris, said:

"We have made good progress since signing our national distribution agreement with Healius. Promarker®D and Promarker®Eso are ready for a controlled market release, with broader national commercial launch expected to commence during Q2 FY27."

"Alongside the Healius rollout, we continue to progress reimbursement strategies and advance Promarker®Endo assay refinement and validation. These activities remain important to the broader commercial development of the Promarker portfolio, and our focus remains on disciplined execution as we progress the commercialisation of the portfolio."

The Company will continue to update the market on material developments in accordance with its continuous disclosure obligations.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

-ENDS-

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr James Williams
Chairman

Mr David Morris
CEO & Managing Director

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Proteomics International Laboratories Ltd
+61 8 9389 1992
E: enquiries@proteomicsinternational.com

Forward Looking Statements

This announcement contains forward-looking statements regarding future events and the future performance of Proteomics International. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied.

Commercial outcomes may depend on factors including implementation timing, clinician adoption, patient utilisation, reimbursement pathways, regulatory requirements where applicable, study outcomes and prevailing market conditions.

These statements are based on information available to the Company as at the date of this announcement and should not be relied upon as guarantees of future performance. Except as required by law, the Company undertakes no obligation to update any forward-looking statements.